News
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway -
-
